Publication:
Biomarkers of fungal infection: Expert opinion on the current situation.

Loading...
Thumbnail Image

Date

2019-11-14

Authors

Bouza, E
Almirante, B
García Rodríguez, J
Garnacho-Montero, J
Salavert, M
Muñoz, P
Sanguinetti, M

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

The introduction of non-culture-based diagnostic techniques is revolutionizing the world of microbiological diagnosis and infection assessment. Fungi are no exception, and the introduction of biomarkers has opened up enormous expectations for better management of these entities. Biomarkers are diverse, their targets are also diverse and their evaluation has been done preferably in an individualized use and with deficient designs. Less is known about the value of the combined use of biomarkers and the impact of the negativity of two or more biomarkers on antifungal treatment decisions has been poorly studied. Given the paucity of prospective, randomized and definitive studies, we have convened experts from different fields, with an interest in invasive fungal infections, to answer some questions about the current relevant use of fungal biomarkers. This document summarizes the answers of these experts to the different questions.

Description

MeSH Terms

Antibodies, Fungal
Aspergillosis
Aspergillus
Biomarkers
Bronchoalveolar Lavage
Candida
Candidemia
False Positive Reactions
Fluorescent Antibody Technique, Indirect
Galactose
Glucans
Humans
Intensive Care Units
Invasive Fungal Infections
Mannans
Sensitivity and Specificity
Spain

DeCS Terms

CIE Terms

Keywords

1-3ß-D-Glucan, Anti-Mannan, CAGTA, Candidemia, Critical Care, Galactomannan, Intensive Care, Invasive candidiasis, Invasive fungal infections, Mannan, T2Candida, antifungal stewardship, fungal biomarkers, invasive aspergillosis

Citation